536 related articles for article (PubMed ID: 18977109)
1. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma.
Yano H; Moran BJ; Cecil TD; Murphy EM
Eur J Surg Oncol; 2009 Sep; 35(9):980-5. PubMed ID: 18977109
[TBL] [Abstract][Full Text] [Related]
2. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Baratti D; Vaira M; Kusamura S; D'Amico S; Balestra MR; Cioppa T; Mingrone E; De Simone M; Deraco M
Eur J Surg Oncol; 2010 Nov; 36(11):1047-53. PubMed ID: 20832234
[TBL] [Abstract][Full Text] [Related]
3. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study.
Brigand C; Monneuse O; Mohamed F; Sayag-Beaujard AC; Isaac S; Gilly FN; Glehen O
Ann Surg Oncol; 2006 Mar; 13(3):405-12. PubMed ID: 16485159
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience.
Chua TC; Yan TD; Morris DL
J Surg Oncol; 2009 Feb; 99(2):109-13. PubMed ID: 19016259
[TBL] [Abstract][Full Text] [Related]
5. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion.
Deraco M; Casali P; Inglese MG; Baratti D; Pennacchioli E; Bertulli R; Kusamura S
J Surg Oncol; 2003 Jul; 83(3):147-53. PubMed ID: 12827682
[TBL] [Abstract][Full Text] [Related]
6. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Oliva GD; Laterza B; Deraco M
Ann Surg Oncol; 2007 Oct; 14(10):2790-7. PubMed ID: 17661150
[TBL] [Abstract][Full Text] [Related]
7. Results of treatment of 33 patients with peritoneal mesothelioma.
Sebbag G; Yan H; Shmookler BM; Chang D; Sugarbaker PH
Br J Surg; 2000 Nov; 87(11):1587-93. PubMed ID: 11091251
[TBL] [Abstract][Full Text] [Related]
8. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Feldman AL; Libutti SK; Pingpank JF; Bartlett DL; Beresnev TH; Mavroukakis SM; Steinberg SM; Liewehr DJ; Kleiner DE; Alexander HR
J Clin Oncol; 2003 Dec; 21(24):4560-7. PubMed ID: 14673042
[TBL] [Abstract][Full Text] [Related]
9. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma.
Yan TD; Yoo D; Sugarbaker PH
Eur J Surg Oncol; 2006 Nov; 32(9):948-53. PubMed ID: 16806796
[TBL] [Abstract][Full Text] [Related]
10. Malignant peritoneal mesothelioma.
Bani-Hani KE; Gharaibeh KA
J Surg Oncol; 2005 Jul; 91(1):17-25. PubMed ID: 15999348
[TBL] [Abstract][Full Text] [Related]
11. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma.
Yan TD; Brun EA; Cerruto CA; Haveric N; Chang D; Sugarbaker PH
Ann Surg Oncol; 2007 Jan; 14(1):41-9. PubMed ID: 17039392
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.
Sugarbaker PH
Eur J Surg Oncol; 2001 Apr; 27(3):239-43. PubMed ID: 11373099
[TBL] [Abstract][Full Text] [Related]
13. Circulating CA125 and diffuse malignant peritoneal mesothelioma.
Baratti D; Kusamura S; Deraco M
Eur J Surg Oncol; 2009 Nov; 35(11):1198-9. PubMed ID: 19423265
[No Abstract] [Full Text] [Related]
14. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
Deraco M; Nonaka D; Baratti D; Casali P; Rosai J; Younan R; Salvatore A; Cabras Ad AD; Kusamura S
Ann Surg Oncol; 2006 Feb; 13(2):229-37. PubMed ID: 16444562
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
Yan TD; Deraco M; Baratti D; Kusamura S; Elias D; Glehen O; Gilly FN; Levine EA; Shen P; Mohamed F; Moran BJ; Morris DL; Chua TC; Piso P; Sugarbaker PH
J Clin Oncol; 2009 Dec; 27(36):6237-42. PubMed ID: 19917862
[TBL] [Abstract][Full Text] [Related]
16. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Dileo P; Laterza B; Deraco M
Ann Surg Oncol; 2009 Feb; 16(2):463-72. PubMed ID: 19082859
[TBL] [Abstract][Full Text] [Related]
17. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma--a prospective study of 70 consecutive cases.
Yan TD; Edwards G; Alderman R; Marquardt CE; Sugarbaker PH
Ann Surg Oncol; 2007 Feb; 14(2):515-25. PubMed ID: 17031722
[TBL] [Abstract][Full Text] [Related]
18. Prospective trial for the treatment of malignant peritoneal mesothelioma.
Loggie BW; Fleming RA; McQuellon RP; Russell GB; Geisinger KR; Levine EA
Am Surg; 2001 Oct; 67(10):999-1003. PubMed ID: 11603562
[TBL] [Abstract][Full Text] [Related]
19. Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma.
Begossi G; Gonzalez-Moreno S; Ortega-Perez G; Fon LJ; Sugarbaker PH
Eur J Surg Oncol; 2002 Feb; 28(1):80-7. PubMed ID: 11869020
[TBL] [Abstract][Full Text] [Related]
20. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma.
Hesdorffer ME; Chabot JA; Keohan ML; Fountain K; Talbot S; Gabay M; Valentin C; Lee SM; Taub RN
Am J Clin Oncol; 2008 Feb; 31(1):49-54. PubMed ID: 18376228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
